Multinationals Step Up Clinical Trials In South Korea
• By PharmAsia News
SEOUL - More and more multinational companies are coming to South Korea to conduct clinical trials, taking advantage of the country's well-trained workforce, well-established infrastructure, lower cost compared with other advanced countries and competitive R&D capability
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers